Ju Hee Oh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ju Hee Oh has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Dae Won Jun
Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea
7 shared publications - Seung Min Lee
Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul 04763, Republic of Korea
3 shared publications - Waqar Khalid Saeed
Department of Internal Medicine, Hanyang University School of Medicine, Seoul, South Korea
3 shared publications - Eileen Laurel Yoon
Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
2 shared publications Hye Young Kim
Department of Translational Medicine, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea
2 shared publications- Hye Young Kim
Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul 04763, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 31 July 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (8) , 943
Biomarker-Driven Optimization of Saponin Therapy in MASLD: From Mouse Models to Human Liver Organoids
(1) Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by liver damage similar to alcoholic fatty liver disease, including triglyceride infiltration of hepatocytes, regardless of alcohol consumption. It leads to progressive liver damage, such as loss of liver function, cirrhosis, and liver cancer, and the response rate of drugs under clinical research is less than 50%. There is an urgent need for biomarkers to evaluate the efficacy of these drugs. (2) Methods: MASLD was induced in mice using a High-Fat diet (HF), Western diet (WD), and Methionine/Choline-Deficient diet (MCD) for 20 weeks (4 weeks for MCD). Liver tissue biopsies were performed, and the treatment effects of saponin and non-saponin feeds were evaluated. Fat accumulation and hepatic inflammation were measured, and mRNA sequencing analysis was conducted. The therapeutic effects were validated using patient-derived liver organoids. (3) Results: The NAFLD Activity Score (NAS) significantly increased in all MASLD models compared with controls. Saponin treatment decreased NAS in the HF and WD groups but not in the MCD group. RNA sequencing and PCA analysis showed that the HF saponin response samples were similar to normal controls. DAVID analysis revealed significant changes in lipid, triglyceride, and fatty acid metabolic processes. qRT-PCR confirmed decreased fibrosis markers in the HF saponin response group, and GSEA analysis showed reduced HAMP1 gene expression. (4) Conclusions: Among the diets, red ginseng was most effective in the HF diet, with significant effects in the saponin-treated group. The therapeutic efficacy was better when HAMP1 expression was increased. Therefore, we propose HAMP1 as a potential exploratory biomarker to assess the saponin response in a preclinical setting. In addition, the reduction of inflammation and hepatic iron accumulation suggests that saponins may exert antioxidant effects through modulation of oxidative stress.
- 31 July 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (8) , 943
Open AccessBiomarker-Driven Optimization of Saponin Therapy in MASLD: From Mouse Models to Human Liver Organoids
(1) Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by liver damage similar to alcoholic fatty liver disease, including triglyceride infiltration of hepatocytes, regardless of alcohol consumption. It leads to progressive liver damage, such as loss of liver function, cirrhosis, and liver cancer, and the response rate of drugs under clinical research is less than 50%. There is an urgent need for biomarkers to evaluate the efficacy of these drugs. (2) Methods: MASLD was induced in mice using a High-Fat diet (HF), Western diet (WD), and Methionine/Choline-Deficient diet (MCD) for 20 weeks (4 weeks for MCD). Liver tissue biopsies were performed, and the treatment effects of saponin and non-saponin feeds were evaluated. Fat accumulation and hepatic inflammation were measured, and mRNA sequencing analysis was conducted. The therapeutic effects were validated using patient-derived liver organoids. (3) Results: The NAFLD Activity Score (NAS) significantly increased in all MASLD models compared with controls. Saponin treatment decreased NAS in the HF and WD groups but not in the MCD group. RNA sequencing and PCA analysis showed that the HF saponin response samples were similar to normal controls. DAVID analysis revealed significant changes in lipid, triglyceride, and fatty acid metabolic processes. qRT-PCR confirmed decreased fibrosis markers in the HF saponin response group, and GSEA analysis showed reduced HAMP1 gene expression. (4) Conclusions: Among the diets, red ginseng was most effective in the HF diet, with significant effects in the saponin-treated group. The therapeutic efficacy was better when HAMP1 expression was increased. Therefore, we propose HAMP1 as a potential exploratory biomarker to assess the saponin response in a preclinical setting. In addition, the reduction of inflammation and hepatic iron accumulation suggests that saponins may exert antioxidant effects through modulation of oxidative stress.
- Open Access
Ticagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease
Background: Previous studies have suggested that platelets are associated with inflammation and steatosis and may play an important role in liver health. Therefore, we evaluated whether antiplatelet agents can improve metabolic disorder-related fatty liver disease (MASLD). Methods: The mice used in the study were fed a high-fat-diet (HFD) and were stratified through liver biopsy at 18 weeks. A total of 22 mice with NAFLD activity scores (NAS) ≥ 4 were randomly divided into three groups (HFD-only, clopidogrel (CLO; 35 mg/kg/day), ticagrelor (TIC; 40 mg/kg/day) group). And then, they were fed a feed mixed with the respective drug for 15 weeks. Blood and tissue samples were collected and used in the study. Results: The TIC group showed a significantly lower degree of NAS and steatosis than the HFD group (p = 0.0047), but no effect on the CLO group was observed. Hepatic lipogenesis markers’ (SREBP1c, FAS, SCD1, and DGAT2) expression and endoplasmic reticulum (ER) stress markers (CHOP, Xbp1, and GRP78) only reduced significantly in the TIC treatment group. Inflammation genes (MCP1 and TNF-α) also decreased significantly in the TIC group, but not in the CLO group. Nile red staining intensity and hepatic lipogenesis markers were reduced significantly in HepG2 cells following TIC treatment. Conclusion: Ticagrelor attenuated NAS and hepatic steatosis in a MASLD mice model by attenuating lipogenesis and inflammation, but not in the CLO group.
Open AccessTicagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease
Background: Previous studies have suggested that platelets are associated with inflammation and steatosis and may play an important role in liver health. Therefore, we evaluated whether antiplatelet agents can improve metabolic disorder-related fatty liver disease (MASLD). Methods: The mice used in the study were fed a high-fat-diet (HFD) and were stratified through liver biopsy at 18 weeks. A total of 22 mice with NAFLD activity scores (NAS) ≥ 4 were randomly divided into three groups (HFD-only, clopidogrel (CLO; 35 mg/kg/day), ticagrelor (TIC; 40 mg/kg/day) group). And then, they were fed a feed mixed with the respective drug for 15 weeks. Blood and tissue samples were collected and used in the study. Results: The TIC group showed a significantly lower degree of NAS and steatosis than the HFD group (p = 0.0047), but no effect on the CLO group was observed. Hepatic lipogenesis markers’ (SREBP1c, FAS, SCD1, and DGAT2) expression and endoplasmic reticulum (ER) stress markers (CHOP, Xbp1, and GRP78) only reduced significantly in the TIC treatment group. Inflammation genes (MCP1 and TNF-α) also decreased significantly in the TIC group, but not in the CLO group. Nile red staining intensity and hepatic lipogenesis markers were reduced significantly in HepG2 cells following TIC treatment. Conclusion: Ticagrelor attenuated NAS and hepatic steatosis in a MASLD mice model by attenuating lipogenesis and inflammation, but not in the CLO group.
- 9 October 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (12) , 2206-2214
Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis
Background and Aim: Necroptosis is an emerging cell death pathway that allows cells to undergo “cellular suicide” in a caspase‐independent manner. We investigated the fate of hepatic stellate cells (HSCs) under necroptotic stimuli.Methods and Results: The RNA level of mixed lineage kinase domain‐like protein (MLKL) is higher in patients with non‐alcoholic fatty liver disease than in healthy controls. Hepatic fibrosis was significantly lower in MLKL‐KO bile duct ligation (KO‐BDL) mice than in wild‐type‐BDL mice. Necroptotic stimuli caused the death of HT‐29 and U937 cells. However, necroptotic stimuli activate HSCs instead of inducing cell death. MLKL inhibitors attenuated fibrogenic changes in HSCs during necroptosis. Unlike HT‐29 and U937 cells, MLKL phosphorylation and oligomerization were not observed during necroptosis in HSCs. RNA sequencing showed that NF‐κB signaling‐related genes were upregulated in HSCs following necroptotic stimulation. Necroptotic stimuli in HSCs increased the nuclear expression of NF‐κB, which decreased after MLKL inhibitor treatment. Induction of necroptosis in HSCs led to autophagosome activation and formation, which were attenuated by MLKL inhibitor treatment.Conclusion: HSCs avoid necroptosis due to the absence of MLKL phosphorylation and oligomerization and are activated through autophagosome and NF‐κB pathways.
- 9 October 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (12) , 2206-2214
Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis
Background and Aim: Necroptosis is an emerging cell death pathway that allows cells to undergo “cellular suicide” in a caspase‐independent manner. We investigated the fate of hepatic stellate cells (HSCs) under necroptotic stimuli.Methods and Results: The RNA level of mixed lineage kinase domain‐like protein (MLKL) is higher in patients with non‐alcoholic fatty liver disease than in healthy controls. Hepatic fibrosis was significantly lower in MLKL‐KO bile duct ligation (KO‐BDL) mice than in wild‐type‐BDL mice. Necroptotic stimuli caused the death of HT‐29 and U937 cells. However, necroptotic stimuli activate HSCs instead of inducing cell death. MLKL inhibitors attenuated fibrogenic changes in HSCs during necroptosis. Unlike HT‐29 and U937 cells, MLKL phosphorylation and oligomerization were not observed during necroptosis in HSCs. RNA sequencing showed that NF‐κB signaling‐related genes were upregulated in HSCs following necroptotic stimulation. Necroptotic stimuli in HSCs increased the nuclear expression of NF‐κB, which decreased after MLKL inhibitor treatment. Induction of necroptosis in HSCs led to autophagosome activation and formation, which were attenuated by MLKL inhibitor treatment.Conclusion: HSCs avoid necroptosis due to the absence of MLKL phosphorylation and oligomerization and are activated through autophagosome and NF‐κB pathways.
- 11 September 2023
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 6 (10) , 1471-1479
Novel Inhibitor of Mixed-Lineage Kinase Domain-Like Protein: The Antifibrotic Effects of a Necroptosis Antagonist
The pseudokinase mixed-lineage kinase domain-like protein plays a crucial role in programmed cell death via necroptosis. We developed a novel mixed-lineage kinase domain-like inhibitor, P28, which demonstrated potent necroptosis inhibition and antifibrotic effects. P28 treatment directly inhibited mixed-lineage kinase domain-like phosphorylation and oligomerization after necroptosis induction, inhibited immune cell death after necroptosis, and reduced the expression of adhesion molecules. Additionally, P28 treatment reduced the level of activation of hepatic stellate cells and the expression of hepatic fibrosis markers induced by necroptosis stimulation. Unlike the necrosulfonamide treatment, the P28 treatment did not induce cytotoxicity. Finally, the cysteine covalent bonding of P28 was confirmed by liquid chromatography-tandem mass spectrometry.
- 11 September 2023
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 6 (10) , 1471-1479
Novel Inhibitor of Mixed-Lineage Kinase Domain-Like Protein: The Antifibrotic Effects of a Necroptosis Antagonist
The pseudokinase mixed-lineage kinase domain-like protein plays a crucial role in programmed cell death via necroptosis. We developed a novel mixed-lineage kinase domain-like inhibitor, P28, which demonstrated potent necroptosis inhibition and antifibrotic effects. P28 treatment directly inhibited mixed-lineage kinase domain-like phosphorylation and oligomerization after necroptosis induction, inhibited immune cell death after necroptosis, and reduced the expression of adhesion molecules. Additionally, P28 treatment reduced the level of activation of hepatic stellate cells and the expression of hepatic fibrosis markers induced by necroptosis stimulation. Unlike the necrosulfonamide treatment, the P28 treatment did not induce cytotoxicity. Finally, the cysteine covalent bonding of P28 was confirmed by liquid chromatography-tandem mass spectrometry.
- Open Access
- 15 February 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16 (1) , 245
Changes in the Brain in Temporal Lobe Epilepsy with Unilat-eral Hippocampal Sclerosis: Initial Case Series
- 15 February 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16 (1) , 245
Open AccessChanges in the Brain in Temporal Lobe Epilepsy with Unilat-eral Hippocampal Sclerosis: Initial Case Series
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (3)
Preclinical investigation of patient-derived cervical cancer organoids for precision medicine
Seol HS, et al. J Gynecol Oncol. 2022 Dec;34:e35. https://doi.org/10.3802/jgo.2023.34.e35
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (3)
Open AccessPreclinical investigation of patient-derived cervical cancer organoids for precision medicine
Seol HS, et al. J Gynecol Oncol. 2022 Dec;34:e35. https://doi.org/10.3802/jgo.2023.34.e35
- Open Access
Regulation of Hepatocyte Nuclear Factor 4α Attenuated Lipotoxicity but Increased Bile Acid Toxicity in Non-Alcoholic Fatty Liver Disease
Hepatocyte nuclear factor 4 alpha (HNF4α) is a key master transcriptional factor for hepatic fat and bile acid metabolic pathways. We aimed to investigate the role of HNF4α in non-alcoholic fatty liver disease (NAFLD). The role of HNF4α was evaluated in free fatty acid–induced lipotoxicity and chenodeoxycholic acid (CDCA)-induced bile acid toxicity. Furthermore, the role of HNF4α was evaluated in a methionine choline deficiency (MCD)-diet-induced NAFLD model. The overexpression of HNF4α reduced intracellular lipid contents and attenuated palmitic acid (PA)-induced lipotoxicity. However, the protective effects of HNF4α were reversed when CDCA was used in a co-treatment with PA. HNF4α knockdown recovered cell death from bile acid toxicity. The inhibition of HNF4α decreased intrahepatic inflammation and the NAFLD activity score in the MCD model. Hepatic HNF4α inhibition can attenuate bile acid toxicity and be more effective as a therapeutic strategy in NAFLD patients; however, it is necessary to study the optimal timing of HNF4α inhibition.
Open AccessRegulation of Hepatocyte Nuclear Factor 4α Attenuated Lipotoxicity but Increased Bile Acid Toxicity in Non-Alcoholic Fatty Liver Disease
Hepatocyte nuclear factor 4 alpha (HNF4α) is a key master transcriptional factor for hepatic fat and bile acid metabolic pathways. We aimed to investigate the role of HNF4α in non-alcoholic fatty liver disease (NAFLD). The role of HNF4α was evaluated in free fatty acid–induced lipotoxicity and chenodeoxycholic acid (CDCA)-induced bile acid toxicity. Furthermore, the role of HNF4α was evaluated in a methionine choline deficiency (MCD)-diet-induced NAFLD model. The overexpression of HNF4α reduced intracellular lipid contents and attenuated palmitic acid (PA)-induced lipotoxicity. However, the protective effects of HNF4α were reversed when CDCA was used in a co-treatment with PA. HNF4α knockdown recovered cell death from bile acid toxicity. The inhibition of HNF4α decreased intrahepatic inflammation and the NAFLD activity score in the MCD model. Hepatic HNF4α inhibition can attenuate bile acid toxicity and be more effective as a therapeutic strategy in NAFLD patients; however, it is necessary to study the optimal timing of HNF4α inhibition.
- 25 October 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (11) , e21979
BTT‐105 ameliorates hepatic fibrosis in non‐alcoholic fatty liver animal model
BTT‐105 (1‐O‐hexyl‐2,3,5‐trimethylhydroquinone), a hydroquinone derivative, is a potent anti‐oxidant that was safe and tolerable in phase I clinical trial. This study examined the anti‐fibrotic effect of BTT‐105 in a mouse model of non‐alcoholic fatty liver disease (NAFLD) along with the underlying mechanisms. In vivo, efficacy of BTT‐105 evaluated from three kinds of NAFLD models (methionine/choline deficient diet (MCD), high fat diet (HF) and western diet (WD)). Metabolomics and transcriptomics profiling analysis in liver tissues were conducted. In vitro, anti‐fibrotic effect of BTT‐105 assessed in human hepatic stellated cells (HSCs) and primary mouse HSCs. BTT‐105 improved NAFLD activity score in three kinds of NAFLD animal models (MCD, HF, and WD). BTT‐105 also decreased levels of hepatic pro‐collagen and collagen fibers deposition in liver tissue. Metabolome and transcriptome analysis revealed that BTT‐105 decreased lipid metabolites and increased antioxidants in NAFLD mice. In HepG2 cells, BTT‐105 enhanced Nrf2‐ARE reporter activity in a dose‐dependent manner and increased the levels of antioxidant gene expression. BTT‐105 showed inhibition of HSCs activation and migration. Gene expression profiling and protein expression showed that BTT‐105 increased Nrf2 activation as well as decreased PI3K‐Akt pathway in activated HSCs. BTT‐105 attenuated ameliorates steatohepatitis and hepatic fibrosis.
- 25 October 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (11) , e21979
BTT‐105 ameliorates hepatic fibrosis in non‐alcoholic fatty liver animal model
BTT‐105 (1‐O‐hexyl‐2,3,5‐trimethylhydroquinone), a hydroquinone derivative, is a potent anti‐oxidant that was safe and tolerable in phase I clinical trial. This study examined the anti‐fibrotic effect of BTT‐105 in a mouse model of non‐alcoholic fatty liver disease (NAFLD) along with the underlying mechanisms. In vivo, efficacy of BTT‐105 evaluated from three kinds of NAFLD models (methionine/choline deficient diet (MCD), high fat diet (HF) and western diet (WD)). Metabolomics and transcriptomics profiling analysis in liver tissues were conducted. In vitro, anti‐fibrotic effect of BTT‐105 assessed in human hepatic stellated cells (HSCs) and primary mouse HSCs. BTT‐105 improved NAFLD activity score in three kinds of NAFLD animal models (MCD, HF, and WD). BTT‐105 also decreased levels of hepatic pro‐collagen and collagen fibers deposition in liver tissue. Metabolome and transcriptome analysis revealed that BTT‐105 decreased lipid metabolites and increased antioxidants in NAFLD mice. In HepG2 cells, BTT‐105 enhanced Nrf2‐ARE reporter activity in a dose‐dependent manner and increased the levels of antioxidant gene expression. BTT‐105 showed inhibition of HSCs activation and migration. Gene expression profiling and protein expression showed that BTT‐105 increased Nrf2 activation as well as decreased PI3K‐Akt pathway in activated HSCs. BTT‐105 attenuated ameliorates steatohepatitis and hepatic fibrosis.
- Open Access
- 31 December 2019
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 40 (1) , 109-119
Taxotere Induces Dephosphorylation of MET in Patient-derived Tumor Models
Background/Aim: Although molecular targeting therapy is an attractive treatment for cancer, resistance eventually develops in most cases. Here, we evaluated chemotherapeutic efficacy on non-small cell lung cancer (NSCLC) with acquired resistance to epidermal growth factor receptor inhibitors mechanistically. Materials and Methods: Antitumor effects of taxotere were evaluated using multiple models, including xenograft, and patient-derived models developed from adenocarcinoma cancer patients. Protein expressions were analyzed after drug treatment. Results: Taxotere inhibited tumor growth of NSCLC cells harboring drug resistance, and reduced the expression of phosphorylated MET proto-oncogene, receptor tyrosine kinase (MET). A tumor-inhibitory effect of taxotere was also demonstrated in vivo in xenografts in mice, patient-derived primary lung tumor cells and patient-derived xenograft with concomitant repression of phosphorylated MET expression. Chemotherapeutic and MET-targeting drug exhibited a synergistic cell growth-inhibitory effect. Conclusion: These results suggest that the anticancer drug taxane may be an adjuvant for lung tumors exhibiting enhanced signaling of MET networks.
- 31 December 2019
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 40 (1) , 109-119
Open AccessTaxotere Induces Dephosphorylation of MET in Patient-derived Tumor Models
Background/Aim: Although molecular targeting therapy is an attractive treatment for cancer, resistance eventually develops in most cases. Here, we evaluated chemotherapeutic efficacy on non-small cell lung cancer (NSCLC) with acquired resistance to epidermal growth factor receptor inhibitors mechanistically. Materials and Methods: Antitumor effects of taxotere were evaluated using multiple models, including xenograft, and patient-derived models developed from adenocarcinoma cancer patients. Protein expressions were analyzed after drug treatment. Results: Taxotere inhibited tumor growth of NSCLC cells harboring drug resistance, and reduced the expression of phosphorylated MET proto-oncogene, receptor tyrosine kinase (MET). A tumor-inhibitory effect of taxotere was also demonstrated in vivo in xenografts in mice, patient-derived primary lung tumor cells and patient-derived xenograft with concomitant repression of phosphorylated MET expression. Chemotherapeutic and MET-targeting drug exhibited a synergistic cell growth-inhibitory effect. Conclusion: These results suggest that the anticancer drug taxane may be an adjuvant for lung tumors exhibiting enhanced signaling of MET networks.
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Korean Medical Science
- Vol. 34 (2) , e14
Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies
Chae YJ, et al. J Korean Med Sci. 2018 Dec;34(2):e14. https://doi.org/10.3346/jkms.2019.34.e14
- 1 January 2019
- Published by XMLink in Journal of Korean Medical Science
- Vol. 34 (2) , e14
Open AccessFeasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies
Chae YJ, et al. J Korean Med Sci. 2018 Dec;34(2):e14. https://doi.org/10.3346/jkms.2019.34.e14